Correspondence
Meghan Higman, MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Roswell Park Comprehensive Cancer Center
Clinical Assistant Professor, Division of Pediatric Hematology/Oncology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Buffalo, New York 14203, USA
e-mail: meghan.higman@roswellpark.org
REFERENCES
1. Britten O, Ragusa D, Tosi S, Kamel YM. MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy? Cells. 2019;8(11).
2. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250.
3. Tomizawa D. Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatr Int. 2015;57(5):811-819.
4. Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr. 2017;5:4.
5. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.Leukemia. 2003;17(4):700-706.
6. Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol.2011;29(2):214-222.
7. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood.2004;104(12):3527-3534.
8. Tomizawa D, Koh K, Hirayama M, et al. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.Pediatr Blood Cancer. 2009;52(7):808-813.
9. Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood.2010;116(15):2644-2650.
10. Grupp SA. Advances in T-cell therapy for ALL. Best Pract Res Clin Haematol. 2014;27(3-4):222-228.
11. Jacobsohn DA, Hewlett B, Morgan E, Tse W, Duerst RE, Kletzel M. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(12):999-1005.
12. Koh K, Tomizawa D, Moriya Saito A, et al. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.Leukemia. 2015;29(2):290-296.
13. Pulsipher MA, Wayne AS, Schultz KR. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.Bone Marrow Transplant. 2014;49(10):1259-1265.
14. Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.Blood Cancer J. 2019;9(2):10.
15. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med.2014;371(16):1507-1517.
16. O’Leary MC, Lu X, Huang Y, et al. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Clin Cancer Res.2019;25(4):1142-1146.
17. Michon B, Moghrabi A, Winikoff R, et al. Complications of apheresis in children. Transfusion. 2007;47(10):1837-1842.
18. Shyr DC, Homsombath AA, Chan PP, Boyer MW, Harris AC. Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia. Pediatr Blood Cancer.2020;67(4):e28155.
19. Wong EC, Balogun RA. Therapeutic apheresis in pediatrics: technique adjustments, indications and nonindications, a plasma exchange focus.J Clin Apher. 2012;27(3):132-137.
20. Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45-63.
21. Pahys J, Fisher V, Carneval M, Yomtovian R, Sarode R, Nieder M. Successful large volume leukapheresis on a small infant allogeneic donor. Bone Marrow Transplant. 2000;26(3):339-341.
22. Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018;8(10):1219-1226.
23. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.